Eventide Asset Management LLC Makes New $1.16 Million Investment in Inventiva S.A. Sponsored ADR $IVA

Eventide Asset Management LLC acquired a new position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) during the 4th quarter, Holdings Channel reports. The fund acquired 250,000 shares of the company’s stock, valued at approximately $1,155,000.

Other large investors also recently added to or reduced their stakes in the company. UBS Group AG increased its stake in Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after acquiring an additional 2,634,580 shares during the last quarter. Propel Bio Management LLC bought a new stake in Inventiva during the fourth quarter worth approximately $4,650,000. Simplify Asset Management Inc. bought a new stake in Inventiva during the fourth quarter worth approximately $1,570,000. SymBiosis Capital Partners LLC bought a new stake in Inventiva during the fourth quarter worth approximately $12,090,000. Finally, Franklin Resources Inc. bought a new stake in Inventiva during the fourth quarter worth approximately $11,626,000. 19.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on IVA shares. Wall Street Zen cut Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Truist Financial started coverage on Inventiva in a research note on Thursday, March 19th. They set a “buy” rating and a $13.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Inventiva has an average rating of “Buy” and a consensus price target of $16.56.

Inventiva Price Performance

IVA opened at $3.85 on Monday. The stock’s 50 day moving average price is $5.07 and its 200-day moving average price is $5.40. Inventiva S.A. Sponsored ADR has a one year low of $2.85 and a one year high of $7.98.

Inventiva (NASDAQ:IVA) last released its earnings results on Sunday, February 15th. The company reported ($0.16) EPS for the quarter. The firm had revenue of $0.01 million during the quarter. Equities analysts forecast that Inventiva S.A. Sponsored ADR will post -0.79 earnings per share for the current year.

Inventiva Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.